"sorry but BK is not in the cards"....no company is immune; not even GTC. I certainly hope that all the past promises and statements that haven't come to pass will be a non-issue based on the partnership announcement we expect by the end of June...but???????
As a shareholder I would hope that it wouldn't come to GTC failing but I'm not so sure. We've made our investment in this company based upon the "solid" technology and "future" earnings potential. I reiterate; if it so clear to us they should have potential partners falling over each other to grab a share? If you assume that the best deal that could have been made was being negotiated with a partner that withdrew from negotiations in the 11th hour, does that mean we are now negotiating for the 2nd best offer? I certainly hope June doesn't pass without a deal, that would be a serious problem.
jesse, I respect your opinions but ... in the interest of accuracy ...
The money GTC owes is not even pocket change for GE. Leo could probably walk away from ATryn and save money at this point. I suppose Merrimac is dependent for their product, but GTC does not provide product for LFB or Pharmathene (for Protexia). The LFB collaborations are all still pre-clinical and Pharmathene receives only consulting services from GTC. (Pharmathene has their own goat herd.)
Maybe Merrimac will pull GTC's chestnuts out of the fire.
Good points about dependency on Leo LFB etc to help with financial situation. How exactly do you forsee our current partners helping financially? Do you think GTCB shareholders are going to see significant benifit from the technology with all the threat of dilution, merger at a low price due to the financial situation?
Market Data 
Markets 
AI
